# Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil

> **NCT00524745** · NA · COMPLETED · sponsor: **PATH** · enrollment: 903 (actual)

## Conditions studied

- Dose Schedule Study

## Interventions

- **BIOLOGICAL:** Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine

## Key facts

- **NCT ID:** NCT00524745
- **Lead sponsor:** PATH
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 903 (ACTUAL)
- **Last updated:** 2017-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00524745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00524745, "Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00524745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*